Discover xT CDx, the FDA-approved assay delivering comprehensive insights through tumor + normal DNA sequencing

Tempus 3D Tumor Organoid (TO) Screen Evaluate the efficacy of preclinical compounds, including small molecules, monoclonal antibodies (mAbs), peptides, and ADCs. Space is limited—enroll by March 31, 2025, to secure your spot.

View the Tempus vision.

We’re looking for people who can change the world.